> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# T. Rowe Price Investment Management Reports 8.2% Position In Xenon Without Seeking Control
- URL: https://www.bullished.co/t-rowe-price-investment-management-reports-8-2-position-in-xenon-without-seeking-control-2af5f6b0/
- Published: 2026-11-06T16:11:39.000Z
- Updated: 2026-11-06T16:11:39.000Z
- Description: The investment manager reported 7,905,757 shares, with sole voting authority covering 7,558,551 shares.
- Author: Matteo Parrino
- Tags: SEC Filings, XENE, Industry: Healthcare

T. Rowe Price Investment Management reported an [8.2% position](https://www.sec.gov/Archives/edgar/data/0001897612/000189761226000699/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in Xenon Pharmaceuticals, which develops drugs for neurological and psychiatric disorders, in a passive ownership disclosure filed Friday. The manager certified that the shares were held for ordinary business purposes, rather than to change or influence Xenon’s control.

## 7.9 Million Shares, Different Voting Authority

The reported position covers 7,905,757 common shares on the SEC disclosure’s beneficial-ownership basis. The ownership figures are dated September 30, 2026; Friday is the filing date, not the date of a reported purchase.

T. Rowe Price Investment Management reported [sole voting authority](https://www.sec.gov/Archives/edgar/data/0001897612/000189761226000699/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) for 7,558,551 shares. Its sole authority to dispose of shares covers the full 7,905,757-share position, with no shared voting or disposal authority reported.

The control certification applies to both the purpose and effect of holding the securities. The manager also certified that the position was not connected to participation in a transaction aimed at changing or influencing control, apart from the certification’s exception for specified director-nomination activities.

## Azetukalner Leads Xenon’s Drug Pipeline

Xenon’s main investigational medicine, azetukalner, is undergoing late-stage studies for epilepsy, major depressive disorder and bipolar depression. Its earlier-stage work includes potential medicines for pain and Dravet syndrome, a form of epilepsy.

The company also licenses drug-development rights to Neurocrine Biosciences through a collaboration carrying milestone payments and royalties. Xenon received a $7.5 million milestone payment in February 2025.

Xenon’s market value was $3.6 billion in Friday trading as of 11:07 a.m. ET.

The reported position gives T. Rowe Price Investment Management voting authority over 7,558,551 Xenon shares; the manager’s certification places that authority outside a control-seeking purpose.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — T. Rowe Price Investment Management, Inc. re: XENON PHARMACEUTICALS INC (XENE)](https://www.sec.gov/Archives/edgar/data/0001897612/000189761226000699/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo Finance](https://ca.finance.yahoo.com/quote/XENE/?ref=bullished.co) — Yahoo Finance
- [Xenon to Present at Upcoming Investor Conferences](https://www.globenewswire.com/news-release/2026/11/03/3394743/0/en/xenon-to-present-at-upcoming-investor-conferences.html?ref=bullished.co) — globenewswire.com
- [Xenon to Report Q3 2026 Financial Results on November 9,](https://www.globenewswire.com/news-release/2026/11/02/3393707/0/en/xenon-to-report-q3-2026-financial-results-on-november-9-2026.html?ref=bullished.co) — globenewswire.com